Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma (EECBL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02728882 |
|
Recruitment Status : Unknown
Verified March 2017 by Sinobioway Cell Therapy Co., Ltd..
Recruitment status was: Recruiting
First Posted : April 5, 2016
Last Update Posted : March 23, 2017
|
Sponsor:
Sinobioway Cell Therapy Co., Ltd.
Collaborator:
The First Affiliated Hospital of Anhui Medical University
Information provided by (Responsible Party):
Sinobioway Cell Therapy Co., Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | July 2019 |
| Estimated Study Completion Date : | July 2019 |